Arcturus Therapeutics Holdings Inc. (ARCT)

NGM – Real Time Price. Currency in USD

8.25

-0.39 (-4.46%)

At close: May 12, 2026, 4:00 PM EDT

8.32

+0.07 (0.87%)

Pre-market: May 13, 2026, 5:10 AM EDT

08.05.2026

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

07.05.2026

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.

07.05.2026

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier.

27.04.2026

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings.

25.03.2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.

23.03.2026

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.

05.03.2026

Arcturus Therapeutics to Attend Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events secti.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

03.03.2026

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. “Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the orn.

10.11.2025

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. “We were pleased to share the initial findings of ARCT-032 clinical activity with the CF community last month at the N.

10.11.2025

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.

Arcturus Therapeutics Holdings Inc. (ARCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Arcturus Therapeutics to Attend Upcoming Investor Conference

Videos

No Data

Press releases

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Arcturus Therapeutics to Attend Upcoming Investor Conference

Videos

No Data

Press releases

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Search stocks

Arcturus Therapeutics Holdings Inc. (ARCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Arcturus Therapeutics to Attend Upcoming Investor Conference

Videos

No Data

Press releases

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Arcturus Therapeutics to Attend Upcoming Investor Conference

Videos

No Data

Press releases

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm